A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the ...

American pharma giant Pfizer ($PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded ...

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, ...

It comes days before the FDA's advisory committee will discuss booster shots. The Food and Drug Administration on Wednesday released data from Pfizer's application for COVID-19 vaccine booster doses.

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer is pushing pause on its requested authorization by the U.S. Food and Drug Administration for a two-dose COVID-19 vaccine for kids under five, and will hold off until the 3-dose data is ...

As the spring saw another surge of coronavirus cases across the country, healthcare officials are urging people to get vaccinated. But some social media posts are spreading false claims that the ...

The FDA said Pfizer had collected more data that was necessary to review. The Food and Drug Administration on Friday postponed its review of Pfizer’s COVID-19 vaccine for kids under 5. “We realized ...

When Pfizer acquired Array Biopharma for $11.4 billion three years ago, the focus was its FDA-approved cancer drugs. The buyout also came with drug candidates in development for other diseases, and it ...

Data from a subanalysis of 30 sera from a Phase 2/3 clinical trial of children 5 through 11 years of age show a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third) ...

Pfizer-BioNTech submitted data to the Food and Drug Administration to clear its Covid-19 vaccine for use in children ages 5 to 11, officials announced Tuesday. The FDA is expected to take at least ...